Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Wells III MD, hematologist oncologist at Lexington Health Cancer Center
Expanded cardiovascular outcome The LEADER study reported a significant reduction in an expanded cardiovascular outcome (CV death, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina or heart failure) in patients with CKD treated with liraglutide compared to placebo (RR 0.77, 95% CI 0.670.89
Qiu Y, Burlingame AL, Benet LZ
Health Sci Rep
US$ 22.41
US$ 22.78
US$ 26.11
US$ 27.62
